Combination and Novel Pharmacologic Agents for OAB

Whitney Clearwater, Farzaan Kassam, Arshia Aalami Harandi, Christopher F. Tenggardjaja, Nitya Abraham

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: To evaluate recent literature on combination and novel pharmacologic therapies for overactive bladder (OAB). Recent Findings: Combination therapies demonstrating greater efficacy than monotherapy include combination anticholinergics, anticholinergic plus β-3 agonist, and anticholinergic with behavioral modification, percutaneous tibial nerve stimulation, or sacral neuromodulation. Promising novel therapies include new bladder selective anticholinergics, new β-3 agonists, and gabapentin. Summary: OAB is a symptom complex caused by dysfunction in the interconnected neural, muscular, and urothelial systems that control micturition. Although several therapeutic targets and treatment options exist, complete resolution is not always achieved, discontinuation rate for medical therapy is high, and few patients subsequently progress to third-line treatment options. Recent literature suggests combination therapy diversifying therapeutic targets is more effective than targeting a single pathway and novel treatments targeting additional pathways have promising results.

Original languageEnglish (US)
Pages (from-to)129-141
Number of pages13
JournalCurrent urology reports
Issue number7
StatePublished - Jul 2022


  • Combination therapy
  • Novel therapy
  • Overactive bladder

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Combination and Novel Pharmacologic Agents for OAB'. Together they form a unique fingerprint.

Cite this